Acute Agitation and Aggression Treatment Market - Profitability Lies in the Exclusiveness of Product Portfolio
The number of people suffering from dementia, as found by the World Health Organization (WHO), is estimated to reach 70 million by 2030, and exceed 105 million by 2050. The prevalence of mental health disorders and their progression at a staggering rate is being well-analyzed by government authorities and discerning investors across the world, which is leading to huge investments in the acute agitation and aggression treatment landscape.
With acute agitation and aggression being a common symptom among patients suffering from various types of mental illnesses, the healthcare industry is expending efforts towards developing effective panaceas. In 2018, the acute agitation and aggression treatment market registered a value of ~US$ 2.9 billion, and is projected to represent a compound annual growth rate of ~5 percent during 2019-2027 - finds a recently published Transparency Market Research (TMR) report.
Modern-day individuals give equal attention to mental health and physical health, given the easy access to healthcare information through online and offline channels. Intense research & development activities undertaken for the introduction of novel drugs with high efficiency and potency, coupled with numerous pipeline drugs, are projected to add new growth tangents to the acute agitation and aggression treatment market.
Looking for Customized Insights to build your business for future, ask for a sample report here
No comments:
Post a Comment